Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's disease: a selective review
Recently published guidelines suggest that the most opportune time to treat individuals with Alzheimer's disease is during the preclinical phase of the disease. This is a phase when individuals are defined as clinically normal but exhibit evidence of amyloidosis, neurodegeneration and subtle co...
Gespeichert in:
| Veröffentlicht in: | Alzheimer's research & therapy 2013-11, Vol.5 (6), p.58-58 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 58 |
|---|---|
| container_issue | 6 |
| container_start_page | 58 |
| container_title | Alzheimer's research & therapy |
| container_volume | 5 |
| creator | Rentz, Dorene M Parra Rodriguez, Mario A Amariglio, Rebecca Stern, Yaakov Sperling, Reisa Ferris, Steven |
| description | Recently published guidelines suggest that the most opportune time to treat individuals with Alzheimer's disease is during the preclinical phase of the disease. This is a phase when individuals are defined as clinically normal but exhibit evidence of amyloidosis, neurodegeneration and subtle cognitive/behavioral decline. While our standard cognitive tests are useful for detecting cognitive decline at the stage of mild cognitive impairment, they were not designed for detecting the subtle cognitive variations associated with this biomarker stage of preclinical Alzheimer's disease. However, neuropsychologists are attempting to meet this challenge by designing newer cognitive measures and questionnaires derived from translational efforts in neuroimaging, cognitive neuroscience and clinical/experimental neuropsychology. This review is a selective summary of several novel, potentially promising, approaches that are being explored for detecting early cognitive evidence of preclinical Alzheimer's disease in presymptomatic individuals. |
| doi_str_mv | 10.1186/alzrt222 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3978443</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A534789562</galeid><sourcerecordid>A534789562</sourcerecordid><originalsourceid>FETCH-LOGICAL-b555t-c1550b950b288f803d39ced16a23fd34cd218be914f7ab890922c1aa1b4703673</originalsourceid><addsrcrecordid>eNqFkl2L1DAUhoso7roK_gIJCOrNrPls0xWEYfELFvRCr0Oank4jaVKTdmT3yp9u6swuM6BICAk5z_ue5JwUxVOCzwmR5WvtbuJEKb1XnJJKyFVNanb_YH9SPErpO8ZlSSV_WJxQTkXFGDktfn2JYbDJ-g1qYQsujAP4KSHrkYc5hjFdmz64sLFGO6THMQZtekioCxFNPWTVBGaywaPQoTGCcdb_Ydfupgc7QHyZUGsT6AQXSKMEbuG3gCJsLfx8XDzotEvwZL-eFd_ev_t6-XF19fnDp8v11aoRQkwrQ4TATZ0nlbKTmLWsNtCSUlPWtYyblhLZQE14V-lG1rim1BCtScMrzMqKnRVvd77j3AzQmvzKqJ0aox10vFZBW3Uc8bZXm7BVrK4k5ywbvNkZNDb8w-A4YsKgbhuT1a_26WP4MUOaVK66Aee0hzAnRcoSc5zTkP-jgmNCJaUL-nyHbrQDZX0Xcmaz4GotGK9kLcol9_lfqDxaGKwJHjqbz48ELw4EPWg39Sm4eWlzOgb3VzUxpBShuysHwWr5mYcFeHZY_zvw9iuy38P04pc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1540128221</pqid></control><display><type>article</type><title>Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's disease: a selective review</title><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>Rentz, Dorene M ; Parra Rodriguez, Mario A ; Amariglio, Rebecca ; Stern, Yaakov ; Sperling, Reisa ; Ferris, Steven</creator><creatorcontrib>Rentz, Dorene M ; Parra Rodriguez, Mario A ; Amariglio, Rebecca ; Stern, Yaakov ; Sperling, Reisa ; Ferris, Steven</creatorcontrib><description>Recently published guidelines suggest that the most opportune time to treat individuals with Alzheimer's disease is during the preclinical phase of the disease. This is a phase when individuals are defined as clinically normal but exhibit evidence of amyloidosis, neurodegeneration and subtle cognitive/behavioral decline. While our standard cognitive tests are useful for detecting cognitive decline at the stage of mild cognitive impairment, they were not designed for detecting the subtle cognitive variations associated with this biomarker stage of preclinical Alzheimer's disease. However, neuropsychologists are attempting to meet this challenge by designing newer cognitive measures and questionnaires derived from translational efforts in neuroimaging, cognitive neuroscience and clinical/experimental neuropsychology. This review is a selective summary of several novel, potentially promising, approaches that are being explored for detecting early cognitive evidence of preclinical Alzheimer's disease in presymptomatic individuals.</description><identifier>ISSN: 1758-9193</identifier><identifier>EISSN: 1758-9193</identifier><identifier>DOI: 10.1186/alzrt222</identifier><identifier>PMID: 24257331</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Alzheimer's disease ; Amyloidosis ; Diagnosis ; Neuropsychological tests ; Neurosciences ; Review</subject><ispartof>Alzheimer's research & therapy, 2013-11, Vol.5 (6), p.58-58</ispartof><rights>COPYRIGHT 2013 BioMed Central Ltd.</rights><rights>Copyright © 2013 BioMed Central Ltd. 2013 BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b555t-c1550b950b288f803d39ced16a23fd34cd218be914f7ab890922c1aa1b4703673</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978443/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978443/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24257331$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rentz, Dorene M</creatorcontrib><creatorcontrib>Parra Rodriguez, Mario A</creatorcontrib><creatorcontrib>Amariglio, Rebecca</creatorcontrib><creatorcontrib>Stern, Yaakov</creatorcontrib><creatorcontrib>Sperling, Reisa</creatorcontrib><creatorcontrib>Ferris, Steven</creatorcontrib><title>Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's disease: a selective review</title><title>Alzheimer's research & therapy</title><addtitle>Alzheimers Res Ther</addtitle><description>Recently published guidelines suggest that the most opportune time to treat individuals with Alzheimer's disease is during the preclinical phase of the disease. This is a phase when individuals are defined as clinically normal but exhibit evidence of amyloidosis, neurodegeneration and subtle cognitive/behavioral decline. While our standard cognitive tests are useful for detecting cognitive decline at the stage of mild cognitive impairment, they were not designed for detecting the subtle cognitive variations associated with this biomarker stage of preclinical Alzheimer's disease. However, neuropsychologists are attempting to meet this challenge by designing newer cognitive measures and questionnaires derived from translational efforts in neuroimaging, cognitive neuroscience and clinical/experimental neuropsychology. This review is a selective summary of several novel, potentially promising, approaches that are being explored for detecting early cognitive evidence of preclinical Alzheimer's disease in presymptomatic individuals.</description><subject>Alzheimer's disease</subject><subject>Amyloidosis</subject><subject>Diagnosis</subject><subject>Neuropsychological tests</subject><subject>Neurosciences</subject><subject>Review</subject><issn>1758-9193</issn><issn>1758-9193</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNqFkl2L1DAUhoso7roK_gIJCOrNrPls0xWEYfELFvRCr0Oank4jaVKTdmT3yp9u6swuM6BICAk5z_ue5JwUxVOCzwmR5WvtbuJEKb1XnJJKyFVNanb_YH9SPErpO8ZlSSV_WJxQTkXFGDktfn2JYbDJ-g1qYQsujAP4KSHrkYc5hjFdmz64sLFGO6THMQZtekioCxFNPWTVBGaywaPQoTGCcdb_Ydfupgc7QHyZUGsT6AQXSKMEbuG3gCJsLfx8XDzotEvwZL-eFd_ev_t6-XF19fnDp8v11aoRQkwrQ4TATZ0nlbKTmLWsNtCSUlPWtYyblhLZQE14V-lG1rim1BCtScMrzMqKnRVvd77j3AzQmvzKqJ0aox10vFZBW3Uc8bZXm7BVrK4k5ywbvNkZNDb8w-A4YsKgbhuT1a_26WP4MUOaVK66Aee0hzAnRcoSc5zTkP-jgmNCJaUL-nyHbrQDZX0Xcmaz4GotGK9kLcol9_lfqDxaGKwJHjqbz48ELw4EPWg39Sm4eWlzOgb3VzUxpBShuysHwWr5mYcFeHZY_zvw9iuy38P04pc</recordid><startdate>20131121</startdate><enddate>20131121</enddate><creator>Rentz, Dorene M</creator><creator>Parra Rodriguez, Mario A</creator><creator>Amariglio, Rebecca</creator><creator>Stern, Yaakov</creator><creator>Sperling, Reisa</creator><creator>Ferris, Steven</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TK</scope><scope>5PM</scope></search><sort><creationdate>20131121</creationdate><title>Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's disease: a selective review</title><author>Rentz, Dorene M ; Parra Rodriguez, Mario A ; Amariglio, Rebecca ; Stern, Yaakov ; Sperling, Reisa ; Ferris, Steven</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b555t-c1550b950b288f803d39ced16a23fd34cd218be914f7ab890922c1aa1b4703673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Alzheimer's disease</topic><topic>Amyloidosis</topic><topic>Diagnosis</topic><topic>Neuropsychological tests</topic><topic>Neurosciences</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rentz, Dorene M</creatorcontrib><creatorcontrib>Parra Rodriguez, Mario A</creatorcontrib><creatorcontrib>Amariglio, Rebecca</creatorcontrib><creatorcontrib>Stern, Yaakov</creatorcontrib><creatorcontrib>Sperling, Reisa</creatorcontrib><creatorcontrib>Ferris, Steven</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Alzheimer's research & therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rentz, Dorene M</au><au>Parra Rodriguez, Mario A</au><au>Amariglio, Rebecca</au><au>Stern, Yaakov</au><au>Sperling, Reisa</au><au>Ferris, Steven</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's disease: a selective review</atitle><jtitle>Alzheimer's research & therapy</jtitle><addtitle>Alzheimers Res Ther</addtitle><date>2013-11-21</date><risdate>2013</risdate><volume>5</volume><issue>6</issue><spage>58</spage><epage>58</epage><pages>58-58</pages><issn>1758-9193</issn><eissn>1758-9193</eissn><abstract>Recently published guidelines suggest that the most opportune time to treat individuals with Alzheimer's disease is during the preclinical phase of the disease. This is a phase when individuals are defined as clinically normal but exhibit evidence of amyloidosis, neurodegeneration and subtle cognitive/behavioral decline. While our standard cognitive tests are useful for detecting cognitive decline at the stage of mild cognitive impairment, they were not designed for detecting the subtle cognitive variations associated with this biomarker stage of preclinical Alzheimer's disease. However, neuropsychologists are attempting to meet this challenge by designing newer cognitive measures and questionnaires derived from translational efforts in neuroimaging, cognitive neuroscience and clinical/experimental neuropsychology. This review is a selective summary of several novel, potentially promising, approaches that are being explored for detecting early cognitive evidence of preclinical Alzheimer's disease in presymptomatic individuals.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>24257331</pmid><doi>10.1186/alzrt222</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1758-9193 |
| ispartof | Alzheimer's research & therapy, 2013-11, Vol.5 (6), p.58-58 |
| issn | 1758-9193 1758-9193 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3978443 |
| source | DOAJ Directory of Open Access Journals; PubMed Central Open Access; Springer Nature OA Free Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; SpringerLink Journals - AutoHoldings |
| subjects | Alzheimer's disease Amyloidosis Diagnosis Neuropsychological tests Neurosciences Review |
| title | Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's disease: a selective review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T18%3A50%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Promising%20developments%20in%20neuropsychological%20approaches%20for%20the%20detection%20of%20preclinical%20Alzheimer's%20disease:%20a%20selective%20review&rft.jtitle=Alzheimer's%20research%20&%20therapy&rft.au=Rentz,%20Dorene%20M&rft.date=2013-11-21&rft.volume=5&rft.issue=6&rft.spage=58&rft.epage=58&rft.pages=58-58&rft.issn=1758-9193&rft.eissn=1758-9193&rft_id=info:doi/10.1186/alzrt222&rft_dat=%3Cgale_pubme%3EA534789562%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1540128221&rft_id=info:pmid/24257331&rft_galeid=A534789562&rfr_iscdi=true |